Liver carcinoma
|
0.800 |
CausalMutation
|
disease |
CGI |
|
|
|
Liver carcinoma
|
0.800 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
HPO |
|
|
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
CTD_human |
|
|
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> A recent study has revealed that miR-106b-5p might promote hepatocellular carcinoma (HCC) stemness maintenance and metastasis by targeting PTEN via PI3K/Akt pathway based on HCC cell lines and animal models.Its clinical relevance remains unknown.
|
31406464 |
2019 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
<b>Background:</b> The aim of the present study was to identify diagnostic and prognostic values of minichromosome maintenance (MCM) gene expression in patients with hepatocellular carcinoma (HCC).
|
30026832 |
2018 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
14-3-3ζ up-regulates hypoxia-inducible factor-1α in hepatocellular carcinoma via activation of PI3K/Akt/NF-кB signal transduction pathway.
|
26884855 |
2015 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
8u, a pro-apoptosis/cell cycle arrest compound, suppresses invasion and metastasis through HSP90α downregulating and PI3K/Akt inactivation in hepatocellular carcinoma cells.
|
29321577 |
2018 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Hepatocellular carcinoma is one of the most common malignancies worldwide and evidence suggests that Ras signaling regulates various hallmarks of cancer via regulating several effector pathways such as ERK and PI3K.
|
26104578 |
2015 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
HCC was recently shown to harbor a distinct genetic make-up and the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kiase (PI3K)/AKT signaling pathways are potential targets for anti-cancer agents in the management of recurrent HCC.
|
31443247 |
2019 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
PI3K pathway activation in hepato-biliary carcinomas was analyzed using immunohistochemistry for the downstream targets eIF4-E and phosphorylated 4E-BP1 on tissue microarrays. eIF4-E expression was found in 3/13 intrahepatic CCA (23%), 9/38 extrahepatic CCA (24%), 12/34 gallbladder carcinomas (35%), and 9/61 hepatocellular carcinomas (15%).
|
18181165 |
2008 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
PI3K-AKT pathway was involved in Pyk2-mediated VEGF expression during HCC progression and invasion.
|
22618716 |
2013 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
PI3K/mTOR inhibition prevented moderate heat stress-induced global effects on HCC molecular signaling and cellular function, including decreased cell survival, growth, and proliferation (Z-score, -0.3 to -3.2; <i>P</i> < .001) and increased apoptosis and cell death (Z-score, 0.4-1.1; <i>P</i> < .001).ConclusionModerate heat stress induces PI3K/mTOR/AKT-dependent global effects on hepatocellular carcinoma (HCC) cell survival, function, and death.
|
31335281 |
2019 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
A brand new lncRNA NR027113 was found, which can promote the proliferation, invasion and metastasis of HCC via the PTEN/PI3K/AKT signaling pathway, and may be a potential therapeutic target in the future treatment of HCC.
|
30468465 |
2018 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
A treatment incorporating circ-CDYL interference and traditional enzyme inhibitors targeting PI3K and HIF1AN demonstrated highly effective inhibition of stem-like characteristics and tumor growth in HCC.
|
31148183 |
2020 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.
|
22428038 |
2012 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Activation of phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway was involved in the development of HCC and acquired resistance to sorafenib.
|
29360358 |
2018 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Activation of the PI3K/Akt/mTOR pathway is an important signaling mechanism involved in the development and the progression of liver cancer stem cell (LCSC) population during acquired Sorafenib resistance in advanced hepatocellular carcinoma (HCC).
|
31439713 |
2019 |
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Additionally, 5-HT1D could attenuate tryptophan hydroxylase 1 expression through the PI3K/Akt/cut-like homeobox 1 axis in HCC.
|
30561038 |
2019 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
An ethyl acetate fraction of Artemisia capillaris (ACE-63) induced apoptosis and anti-angiogenesis via inhibition of PI3K/AKT signaling in hepatocellular carcinoma.
|
29972254 |
2018 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Anemoside B4 exerts anti-cancer effect by inducing apoptosis and autophagy through inhibiton of PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
|
31105864 |
2019 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Anti-hepatocarcinoma effect of cordycepin against NDEA-induced hepatocellular carcinomas via the PI3K/Akt/mTOR and Nrf2/HO-1/NF-κB pathway in mice.
|
28968944 |
2017 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line.
|
26311153 |
2015 |
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma.
|
31694662 |
2019 |
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
AT-rich interactive domain 2 (ARID2), catenin (cadherin-associated protein), beta 1, 88kDa (β-catenin), tumor protein 53 (p53), and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (p110α) mutations are implicated in hepatocellular carcinoma (HCC); and previous work has contributed to thorough molecular characterization of these events.
|
25701229 |
2015 |